Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis

• Published in: Evidence-based complementary and alternative medicine Vol. 2021; pp. 1 - 12
• Main Authors: Chen, Kai, Lou, Yu, Zhu, Ying
• Format: Journal Article
• Language: English
• Published: New York Hindawi 09.06.2021; Hindawi Limited
• Subjects: Alternative medicine; Animal models; Bone healing; Chinese medicine; Colon; Cytokines; Diarrhea; Disease; Dosage; Drug dosages; Genes; Immunomodulation; Immunotherapy; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Intestinal microflora; Irritable bowel syndrome; Kinases; Liver; Medical research; Mesenchyme; Mucosa; Pathogenesis; Proteins; R&D; Research & development; Review; Signal transduction; Spleen; Stem cell transplantation; Stem cells; Tumor necrosis factor-TNF; Ulcerative colitis
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2021/5548764

The prescription of Tong Xie Yao Fang (TXYF) was derived from the Yuan dynasty “Dan Brook Heart Law,” which was a representative formula for treating liver-spleen disharmony, diarrhea, and abdominal pain. The prescription is composed of four herbs for soothing the liver and strengthening the spleen. TXYF is reportedly capable of eliminating discomfort in ulcerative colitis (UC). This classic formula has been widely used for regulating gastrointestinal motor dysfunction and repairing colon mucosa. This review aims to provide current information on the pharmacology and clinical research of TXYF in the treatment of UC, and to critically appraise that information, in order to guide the future clinical use and experimental study of TXYF in the treatment of UC. We searched online databases including PubMed, CNKI, and Google Scholar for research published between 2010 and 2020 on TXYF and its efficacy in the treatment of UC. The findings indicated that TXYF has anti-inflammatory and immunomodulatory effects, regulates cell signal transduction, brain-gut axis, and intestinal flora in UC, and may promote targeting of bone mesenchymal stem cells (BMSCs) to the colonic mucosa and accelerate healing of the colonic mucosal barrier. In addition, the results of clinical studies showed that TXYF has good efficacy and few adverse reactions in the treatment of UC. Although it has achieved some success, the research is limited by deficiencies; there is a lack of unified standards for the construction of UC animal models and for administration regimen. In addition, the dosage of TXYF is not consistent and lacks pharmacological verification, and clinical trial data are not detailed or sufficiently rigorous. Therefore, a more rigorous, comprehensive, and in-depth study of TXYF in the treatment of UC is needed.